Emcure Pharmaceuticals: Promoter Disclosure under SEBI Takeover Regulation 31(4)

Regulatory 24 Jun 2026 · Filed / open· ✓ Verified

The disclosure was filed with NSE on 24 June 2026 by four named promoters of Emcure Pharmaceuticals Limited, a listed pharmaceutical manufacturer. Regulation 31(4) of the SEBI Takeover Regulations mandates disclosure when a person or group acquires 25% or more shares or voting rights, or when a change in control occurs. The identity of all four filers-including executive (Satish, Sunil, Samit Mehta) and non-executive (Namita Thapar) shareholders-suggests a coordinated promoter action, likely a consolidation, pledge release, or cross-holding restructuring within the family. The regulatory filing creates a public record and may trigger open-offer or exemption determinations under SEBI rules.

Why it mattersRegulation 31(4) disclosures trigger public awareness and regulatory scrutiny of insider control shifts; practitioners must verify whether the acquisition crosses the 25% threshold or involves concert-party aggregation, as these gates open additional SEBI conditions and reverse-takeover risk.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals